Joachim von Pawel

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 3.2K citations

Medicine, Oncology, Pharmacology +16

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2004 · 2.4K citations · Full text

Medicine, Oncology, Pharmacology +15

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

Medicine, Oncology, Palliative Oncology +9

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giuseppe Giaccone, Roy S. Herbst, Christian Manegold et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +13